Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
CDC shortens 14-day quarantine recommendation to 7 to 10 days
The Centers for Disease Control and Prevention is shortening the recommended quarantine period from 14 days after a person...
-
Rare disorder causes man to see ‘demonic’ faces
Victor Sharrah had always had sharp vision. But one life-altering day in November 2020, he noticed out of the...
-
South Africa lifts curfew as it says omicron-driven Covid wave peaks
CAPE TOWN — South Africa has lifted a midnight to 4 a.m. curfew on people’s movement with immediate effect,...
-
Patients with private insurance can face higher health costs at hospitals
People with private health insurance might pay higher prices for procedures or tests at a hospital. A report published...
-
Britain cut adrift as mutant virus strain prompts global alarm
LONDON — The United Kingdom found itself increasingly cut adrift from the outside world Monday as countries took drastic...
-
Virus spread from day care to parents and teachers, CDC says
Very young children can catch COVID-19 and spread the virus to adults, even if they never show symptoms, according...
-
Mediterranean diet may reduce or prevent PTSD symptoms, new research shows
A Mediterranean diet that’s rich in vegetables, fruits and fish may help reduce or stave off symptoms of post-traumatic...
-
FDA recommends including omicron subvariants BA.4 and BA.5 in fall Covid boosters
The next round of Covid booster shots should be modified to target the extremely contagious omicron subvariants BA.4 and...
Recent Comments